Interleukin (IL)-6 has emerged as a potential new target in the treatment of renal disease in patients with systemic lupus erythematosus (SLE), according to a report by Hannes Cash et al., ...
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...
A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...
Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...
More information: Henry W. Chen et al, Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus, JAMA Dermatology (2024). DOI: 10.1001/jamadermatol.2024.4991 ...
Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...
[2] Table 1. Onset, pathology, physical examination findings and recommended physical therapy interventions for systematic lupus erythematosus, rheumatoid arthritis, osteoarthritis, osteoporosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback